Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29020427 | 0.97 | ALDH1A1 (0.45) | ALDH1A1TSHRL3MBTL1HMGCRCHRM1 | |
| SCHEMBL13742242 | 0.77 | ALDH1A1 (0.33) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL10388008 | 0.77 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1HMGCRCHRM1 | |
| SCHEMBL866857 | 0.73 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL27715552 | 0.73 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL29020430 | 0.72 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL29783265 | 0.72 | TSHR (0.43) | ALDH1A1TSHRHMGCRCHRM1TBXA2R | |
| Pivalate SCHEMBL28392338 | 0.71 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1HMGCRCHRM1 | |
| SCHEMBL6632023 | 0.71 | ALDH1A1 (0.43) | ALDH1A1TSHRL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL6008936 | 0.70 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102027125-A | Adipate or Thioester Synthesis | DSM IP ASSETS BV | 2011-04-20 | — | — | CN | claimed |
| EP-0956282-B1 | SULPHINIC ACID DERIVATIVES, METHOD FOR PRODUCING THEM, AND THEIR USE | BRUEGGEMANN L KG (DE) | 2002-04-17 | — | — | EP | claimed |
| US-6211400-B1 | CAN BE USED AS REDUCING AGENTS WHICH DO NOT ELIMINATE FORMALDEHYDE | L. BRUGGEMANN KG (DE) | 2001-04-03 | — | — | US | claimed |
| EP-0956282-A1 | SULPHINIC ACID DERIVATIVES, METHOD FOR PRODUCING THEM, AND THEIR USE | L. Brüggemann KG (DE) | 1999-11-17 | — | — | EP | claimed |
| WO-1999018067-A1 | SULPHINIC ACID DERIVATIVES, METHOD FOR PRODUCING THEM, AND THEIR USE | L. Brüggemann KG (DE) | 1999-04-15 | — | — | WO | claimed |
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4594518-A1 | METHOD TO VERIFY THE EFFECTIVENESS OF A STERILIZATION PROCESS BASED ON THE PRESENCE OF VOLATILE ORGANIC COMPOUNDS | O&M Halyard, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250207207-A1 | TAXONOMIC SIGNATURES AND METHODS OF DETERMINING THE SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-26 | — | — | US | disclosed |
| US-12318413-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | disclosed |
| US-12310996-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-27 | — | — | US | disclosed |
| CN-120004771-A | Method for producing organic sulfinate compound | 中国石油化工股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4499878-A2 | TAXONOMIC SIGNATURES AND METHODS OF DETERMINING THE SAME | Baylor College of Medicine (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-102341445-B | Expandable composite resin particles for long-term storage, pre-expanded beads formed therefrom, and molded foam | SEKISUI PLASTICS | 2013-07-03 | — | — | CN | disclosed |
| EP-2547705-A1 | METHOD FOR PRODUCING WATER-ABSORBENT POLYMER PARTICLES HAVING IMPROVED COLOR STABILITY | BASF SE (DE) | 2013-01-23 | — | — | EP | disclosed |
| CN-102361916-A | Method for reducing volatile organic compounds in composite resin particles, and composite resin particles | SEKISUI PLASTICS | 2012-02-22 | — | — | CN | disclosed |
| CN-102341445-A | Expandable composite resin particles for long-term storage, pre-expanded beads formed therefrom, and molded foam | SEKISUI PLASTICS | 2012-02-01 | — | — | CN | disclosed |
| CN-102264813-A | Pre-expanded particles, process for producing same, and molded foam | — | 2011-11-30 | — | — | CN | disclosed |
| WO-2011113777-A1 | METHOD FOR PRODUCING WATER-ABSORBENT POLYMER PARTICLES HAVING IMPROVED COLOR STABILITY | BASF SE (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-20110224381-A1 | Process for Producing Water Absorbing Polymer Particles with Improved Color stability | BASF SE (DE) | 2011-09-15 | — | — | US | disclosed |
| CN-102027125-A | Adipate or Thioester Synthesis | DSM IP ASSETS BV | 2011-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | PDCD1, CD274, PDCD1LG2 | ALDH1A1 1552/4885TSHR 1153/4885L3MBTL1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.